Loading…
RedHill Biopharma Ltd. is projected to rise to $0.6987 by 2027, a +7% move from its current price of $0.6502. RDHL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.6247 | $0.6508 | $0.6781 | +0.10% |
| Aug 6 | $0.6147 | $0.6515 | $0.6905 | +0.20% |
| Aug 7 | $0.6073 | $0.6521 | $0.7002 | +0.30% |
| Aug 8 | $0.6013 | $0.6528 | $0.7087 | +0.40% |
| Aug 9 | $0.5961 | $0.6534 | $0.7163 | +0.50% |
| Aug 10 | $0.5915 | $0.6541 | $0.7233 | +0.59% |
| Aug 11 | $0.5873 | $0.6547 | $0.7299 | +0.69% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.5873 | $0.6547 | $0.7299 | +0.69% |
| Week 2 | $0.5653 | $0.6593 | $0.7688 | +1.39% |
| Week 3 | $0.5499 | $0.6638 | $0.8013 | +2.10% |
| Week 4 | $0.5379 | $0.6684 | $0.8307 | +2.81% |
| Week 5 | $0.5279 | $0.6731 | $0.8582 | +3.52% |
| Week 6 | $0.5194 | $0.6778 | $0.8845 | +4.24% |
| Week 7 | $0.5119 | $0.6825 | $0.9098 | +4.96% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on gastrointestinal and infectious diseases. It develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.
Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults.
The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
RDHL trades with a current price of $0.6307 and a market cap of $3.84M. Its rank is 5061. The stock’s near-term setup shows a neutral stance with a defined 30-day range and visible support and resistance levels.
Forecasts indicate a mixed to bullish longer-term outlook. For 2026 the min is $0.6307, the avg is $0.6307, the max is $0.8523, with ROI 0 and sentiment NEUTRAL. From 2027 onward, the path suggests gradually higher averages and upside potential, culminating in higher price levels through 2050 as the series progresses.
A major floor 32.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (3.0% away) — a key level to hold.
The nearest ceiling, 42.4% above — a clean break opens room to run.
A major ceiling 67.6% above — clearing it would confirm fresh momentum.
Key RDHL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of RDHL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.6788 | Sell | $0.6645 | Sell |
| MA 10 | $0.677 | Sell | $0.6795 | Sell |
| MA 20 | $0.7007 | Sell | $0.7121 | Sell |
| MA 50 | $0.8264 | Sell | $0.7924 | Sell |
| MA 100 | $0.8641 | Sell | $0.8848 | Sell |
| MA 200 | $1.03 | Sell | $1.43 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.53 | Neutral |
| Stoch RSI (14) | 57.59 | Neutral |
| CCI (20) | -120.84 | Sell |
| Williams %R (14) | -83.04 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -12.52 | Sell |
| Bollinger %B (20,2) | 0.16 | Neutral |
| Stochastic %K (14) | 16.96 | Buy |
| TRIX (15) | -0.90 | Sell |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 42.76 | Neutral |
| Momentum (10) | -0.06 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 0.66 | Sell |
| ADX (14) | 24.40 | Sell |
| ATR (14) | 0.03 | Info |
Near term, sentiment is NEUTRAL with RSI14 at 40. The SMA50 sits at $0.832 and the SMA200 at $1.03. Key support is listed at $0.631 and resistance at $0.926. The stock has a 30-day trading range from $0.4792 to $0.8301, reflecting modest volatility within a tight band.
Annualized volatility stands at 80%, highlighting elevated risk relative to broader markets and the potential for significant intraday movement.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.631 | $0.6502 | $0.8751 | 0% | Neutral | |
| $0.5319 | $0.6987 | $0.9841 | +7% | Neutral | |
| $0.6058 | $0.8323 | $1.24 | +28% | Bullish | |
| $0.6493 | $0.9264 | $1.43 | +42% | Bullish | |
| $0.6011 | $0.887 | $1.42 | +36% | Bullish | |
| $0.5482 | $0.8343 | $1.37 | +28% | Bullish | |
| $0.4823 | $0.7558 | $1.28 | +16% | Neutral | |
| $0.5282 | $0.851 | $1.47 | +31% | Bullish | |
| $0.6763 | $1.12 | $1.98 | +72% | Bullish | |
| $0.65 | $1.10 | $1.99 | +70% | Bullish | |
| $0.7087 | $1.36 | $2.65 | +109% | Bullish | |
| $0.9473 | $2.11 | $4.62 | +224% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.631 | $0.6502 | $0.7743 | +0.00% |
| September 2026 | $0.561 | $0.673 | $0.8367 | +3.51% |
| October 2026 | $0.5869 | $0.7115 | $0.8988 | +5.72% |
| November 2026 | $0.5653 | $0.6912 | $0.8843 | -2.86% |
| December 2026 | $0.5487 | $0.6763 | $0.8751 | -2.16% |
Click any year to see its month-by-month RDHL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
RedHill Biopharma Ltd.'s 2026 outlook centres on $0.6502, within a $0.631 to $0.8751 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, RDHL could reach as high as $0.9841, with a base case around $0.6987 and support toward $0.5319 — roughly +7% from $0.6502. Price action looks broadly range-bound.
Expect RDHL to range from $0.6058 to $1.24 through 2028. The $0.8323 average target implies a +28% move from current prices. That is up +19% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The RDHL price prediction for 2029 points to an average of $0.9264 (low $0.6493, high $1.43) — a potential gain of +42% on today's $0.6502. Momentum favours further upside here.
In 2030, RDHL is projected to trade between $0.6011 and $1.42, averaging $0.887 — a potential gain of +36% from today's $0.6502. That is -4% versus the projected 2029 average. Buyers look set to stay in control over this stretch.
RedHill Biopharma Ltd.'s 2031 outlook centres on $0.8343, within a $0.5482 to $1.37 range. That is -6% versus the projected 2030 average. That marks a +28% change versus current levels. Momentum favours further upside here.
By 2032, RDHL could reach as high as $1.28, with a base case around $0.7558 and support toward $0.4823 — roughly +16% from $0.6502. A consolidation phase looks the most probable path here.
Expect RDHL to range from $0.5282 to $1.47 through 2033. The $0.851 average target implies a +31% move from current prices. That is up +13% on the projected 2032 average. Momentum favours further upside here.
The RDHL price prediction for 2034 points to an average of $1.12 (low $0.6763, high $1.98) — a potential gain of +72% on today's $0.6502. Buyers look set to stay in control over this stretch.
In 2035, RDHL is projected to trade between $0.65 and $1.99, averaging $1.10 — a potential gain of +70% from today's $0.6502. That is -1% versus the projected 2034 average. Momentum favours further upside here.
RedHill Biopharma Ltd.'s 2040 outlook centres on $1.36, within a $0.7087 to $2.65 range. That is up +23% on the projected 2035 average. That marks a +109% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, RDHL could reach as high as $4.62, with a base case around $2.11 and support toward $0.9473 — roughly +224% from $0.6502. Momentum favours further upside here.
Investing $1,000 in RDHL today (≈ 1,537.988311 RDHL) could be worth
$3,237.63
+$2,237.63 (+224%) by 2050 · US Dollar
Based on the average projected RDHL price of $2.11 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in RDHLwould be worth at today's price.
$1,000 invested in RDHL on Jul 31, 2025 (≈ 763.358812 RDHL) would be worth
$496.34
-$503.66 (-50.4%) today · 0.50× · US Dollar
Based on a RDHL entry price of $1.31 vs. today's $0.6502.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.633 | $1,027.17 | +2.7% |
| 1 month ago | $0.83 | $783.37 | -21.7% |
| 3 months ago | $1.09 | $599.26 | -40.1% |
| 6 months ago | $1.15 | $565.39 | -43.5% |
| 1 year ago | $1.31 | $496.34 | -50.4% |
| All time (5.0y) ago | $7,100 | $0.09 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our RDHL forecast.
Our base-case forecast reaches $1.30 around 2040.
Implied market cap at $1.30: $7.91M
The multi-year forecast points to an overall bullish tilt after 2026, with the average price rising from $0.6307 in 2026 to $2.01 by 2050. Notable waypoints include 2027 average $0.6742 and 2028 average $0.7966, then 2029 average $0.9009 and 2030 average $0.8572. The long-horizon view shows 2040 average $1.29 and 2050 average $2.01, with corresponding max prices of $2.53 and $4.45 respectively and ROI figures of 104 and 219.1.
Sentiment in the forecast shifts from NEUTRAL in 2026 to BULLISH in most later years, with occasional Neutral steps such as 2032. The path implies meaningful upside but remains contingent on factors not specified here; these are estimates, not guarantees, and actual results may differ. Investors should consider the inherent uncertainty and the variability of outcomes across the long horizon.
Tap a question to reveal the answer.
2030 avg $0.8572, min $0.5783, max $1.38, ROI 35.9, sentiment BULLISH.
Forecasts show bullish sentiment in several years (including 2028, 2029, 2030, 2031, 2033 onward) with rising averages up to $2.01 by 2050, but 2026 is neutral. These are estimates, not guarantees.
2040 max $2.53 and avg $1.29, with ROI 104 and sentiment BULLISH.
RSI14 is 40, SMA50 $0.832, SMA200 $1.03; support $0.631, resistance $0.926; 30-day range $0.4792–$0.8301; sentiment NEUTRAL.
Current price $0.6307; Market cap $3.84M; Rank 5061.
RedHill Biopharma Ltd. Community Discussion
0Share your RedHill Biopharma Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.